Header

UZH-Logo

Maintenance Infos

Mammalian Epoxide Hydrolases


Arand, Michael; Marowsky, Anne (2018). Mammalian Epoxide Hydrolases. In: Elsevier Inc. Comprehensive Toxicology: Third Edition. Oxford: Elsevier, 308-325.

Abstract

Epoxide hydrolases (EHs) metabolize highly reactive epoxides with mutagenic and carcinogenic potential to the less reactive corresponding diols and are therefore traditionally viewed as detoxicating enzymes. In few instances, however, the diols themselves can be precursors of further reactive metabolites, and EH may thereby contribute to metabolic toxification. The most important xenobiotic-metabolizing EH is the microsomal EH (mEH). Furthermore, evidence is emerging that mammalian EHs fulfill roles other than detoxication. Meanwhile, the role of soluble EH (sEH), whose physiological substrates are epoxyeicosanoids (epoxyeicosatrienoic acids, EETs), signaling molecules involved in a broad variety of regulatory pathways, is well documented. sEH is therefore considered a new drug target as respective inhibitors promise therapeutic potential in the treatment of hypertension, pain, and possibly other diseases. Two new human EHs, EH3 and EH4, have been recently identified. Their expression pattern and substrate specificity strongly suggest a role in physiological processes, similar to sEH, rather than in metabolizing xenobiotic compounds.

Abstract

Epoxide hydrolases (EHs) metabolize highly reactive epoxides with mutagenic and carcinogenic potential to the less reactive corresponding diols and are therefore traditionally viewed as detoxicating enzymes. In few instances, however, the diols themselves can be precursors of further reactive metabolites, and EH may thereby contribute to metabolic toxification. The most important xenobiotic-metabolizing EH is the microsomal EH (mEH). Furthermore, evidence is emerging that mammalian EHs fulfill roles other than detoxication. Meanwhile, the role of soluble EH (sEH), whose physiological substrates are epoxyeicosanoids (epoxyeicosatrienoic acids, EETs), signaling molecules involved in a broad variety of regulatory pathways, is well documented. sEH is therefore considered a new drug target as respective inhibitors promise therapeutic potential in the treatment of hypertension, pain, and possibly other diseases. Two new human EHs, EH3 and EH4, have been recently identified. Their expression pattern and substrate specificity strongly suggest a role in physiological processes, similar to sEH, rather than in metabolizing xenobiotic compounds.

Statistics

Citations

Dimensions.ai Metrics

Altmetrics

Downloads

1 download since deposited on 26 Mar 2018
1 download since 12 months
Detailed statistics

Additional indexing

Item Type:Book Section, refereed, original work
Communities & Collections:04 Faculty of Medicine > Institute of Pharmacology and Toxicology
07 Faculty of Science > Institute of Pharmacology and Toxicology
Dewey Decimal Classification:570 Life sciences; biology
610 Medicine & health
Language:English
Date:December 2018
Deposited On:26 Mar 2018 20:01
Last Modified:20 Sep 2018 04:31
Publisher:Elsevier
Series Name:Reference Module in Biomedical Sciences
Number:10
ISBN:978-0-12-801238-3
OA Status:Closed
Publisher DOI:https://doi.org/10.1016/B978-0-12-801238-3.95622-8

Download